Free Trial
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel Free QDEL Stock Alerts

QuidelOrtho (QDEL) Financials

QuidelOrtho logo
$12.77 +0.63 (+5.18%)
As of 10:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for QuidelOrtho

Annual Income Statements for QuidelOrtho

This table shows QuidelOrtho's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.08 -14 -8.17 74 73 810 704 549 -10 -2,052 -1,132
Consolidated Net Income / (Loss)		 -6.08 -14 -8.17 74 73 810 704 549 -10 -2,052 -1,132
Net Income / (Loss) Continuing Operations		 -6.08 -14 -8.17 74 73 810 704 549 -10 -2,052 -1,132
Total Pre-Tax Income 		-9.30 -16 -8.04 63 77 1,040 900 736 -29 -2,132 -1,108
Total Operating Income		 2.74 -4.44 9.55 96 93 1,060 906 844 139 -1,961 -919
Total Gross Profit		 118 112 156 316 321 1,349 1,278 1,936 1,497 1,287 1,274
Total Revenue		 196 192 278 522 535 1,662 1,699 3,266 2,998 2,783 2,730
Operating Revenue		 196 192 278 522 535 1,662 1,699 3,266 2,998 2,783 2,730
Total Cost of Revenue		 78 80 122 207 214 313 420 1,330 1,501 1,496 1,456
Operating Cost of Revenue		 78 80 122 207 214 313 420 1,330 1,501 1,496 1,456
Total Operating Expenses		 115 116 147 220 228 289 372 1,093 1,358 3,247 2,193
Selling, General & Admin Expense		 27 26 29 45 53 67 240 633 790 819 844
Research & Development Expense		 36 39 34 52 53 84 96 188 245 219 186
Amortization Expense		 - - - - - - 27 133 205 203 189
Impairment Charge		 - - - - - - - 2.80 4.50 1,880 710
Restructuring Charge		 2.39 0.71 17 14 12 3.69 9.60 136 113 127 264
Total Other Income / (Expense), net		 -12 -12 -18 -33 -16 -20 -5.70 -108 -168 -171 -189
Interest Expense		 - -0.42 0.00 8.26 0.75 10 5.80 100 148 164 183
Other Income / (Expense), net		 - - - - - - 0.10 -8.10 -21 -7.10 -5.80
Income Tax Expense		 -3.22 -2.39 0.13 -11 4.26 230 196 187 -19 -80 24
Basic Earnings per Share		 ($0.18) ($0.42) ($0.24) $1.95 $1.78 $19.24 $16.74 $9.66 ($0.15) ($30.54) ($16.69)
Weighted Average Basic Shares Outstanding		 34.10M 32.71M 33.73M 38.00M 40.86M 42.12M 42.10M 56.80M 66.80M 67.20M 67.80M
Diluted Earnings per Share		 ($0.18) ($0.42) ($0.24) $1.86 $1.73 $18.60 $16.43 $9.56 ($0.15) ($30.54) ($16.69)
Weighted Average Diluted Shares Outstanding		 34.10M 32.71M 33.73M 42.55M 43.11M 43.59M 42.90M 57.40M 66.80M 67.20M 67.80M
Weighted Average Basic & Diluted Shares Outstanding		 34.10M 32.71M 34M 38.00M 41M 42.32M - - 66.85M 67.45M 68.08M

Quarterly Income Statements for QuidelOrtho

This table shows QuidelOrtho's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1,706 -148 -20 -178 -13 -255 -733 -131 -92 -93
Consolidated Net Income / (Loss)		 -1,706 -148 -20 -178 -13 -255 -733 -131 -92 -93
Net Income / (Loss) Continuing Operations		 -1,706 -148 -20 -178 -13 -255 -733 -131 -92 -93
Total Pre-Tax Income 		-1,799 -163 -29 -141 -8.80 -230 -757 -112 -80 -81
Total Operating Income		 -1,758 -118 15 -100 33 -181 -705 -66 -32 -22
Total Gross Profit		 332 276 352 326 343 275 336 320 264 273
Total Revenue		 711 637 727 708 693 614 700 724 620 631
Operating Revenue		 711 637 727 708 693 614 700 724 620 631
Total Cost of Revenue		 379 361 375 382 350 339 364 403 356 358
Operating Cost of Revenue		 379 361 375 382 350 339 364 403 356 358
Total Operating Expenses		 2,090 394 337 427 311 456 1,040 387 296 295
Selling, General & Admin Expense		 213 198 193 216 193 183 201 266 200 191
Research & Development Expense		 59 56 56 47 53 46 42 46 45 49
Amortization Expense		 52 52 52 48 48 48 48 46 47 49
Restructuring Charge		 23 31 37 37 16 179 40 29 4.40 6.50
Total Other Income / (Expense), net		 -41 -45 -44 -41 -41 -49 -52 -46 -48 -59
Interest Expense		 39 41 43 41 40 41 51 51 51 55
Other Income / (Expense), net		 -1.90 -4.40 -0.90 0.10 -1.40 -8.40 -0.90 4.90 3.40 -4.70
Income Tax Expense		 -93 -15 -8.90 38 3.90 26 -24 18 12 12
Basic Earnings per Share		 ($25.50) ($2.20) ($0.30) ($2.54) ($0.19) ($3.77) ($10.78) ($1.95) ($1.35) ($1.36)
Weighted Average Basic Shares Outstanding		 66.90M 67.10M 67.30M 67.20M 67.50M 67.70M 68M 67.80M 68.20M 68.30M
Diluted Earnings per Share		 ($25.50) ($2.20) ($0.30) ($2.54) ($0.19) ($3.77) ($10.78) ($1.95) ($1.35) ($1.36)
Weighted Average Diluted Shares Outstanding		 66.90M 67.10M 67.30M 67.20M 67.50M 67.70M 68M 67.80M 68.20M 68.30M
Weighted Average Basic & Diluted Shares Outstanding		 - 67.24M 67.26M 67.45M 67.63M 67.90M 67.93M 68.08M 68.19M 68.58M

Annual Cash Flow Statements for QuidelOrtho

This table details how cash moves in and out of QuidelOrtho's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Change in Cash & Equivalents		 -9.42 -22 -133 7.61 9.08 437 313 -509 -174 -21 71
Net Cash From Operating Activities		 37 12 28 136 134 630 806 885 280 83 105
Net Cash From Continuing Operating Activities		 37 12 28 136 134 630 806 885 280 83 105
Net Income / (Loss) Continuing Operations		 -6.08 -14 -8.17 74 73 810 704 549 -10 -2,052 -1,132
Consolidated Net Income / (Loss)		 -6.08 -14 -8.17 74 73 810 704 549 -10 -2,052 -1,132
Depreciation Expense		 23 23 31 46 48 49 53 284 457 453 442
Non-Cash Adjustments To Reconcile Net Income		 7.33 7.08 12 15 25 40 20 144 46 1,942 914
Changes in Operating Assets and Liabilities, net		 6.58 -10 -23 -5.95 -13 -271 29 -91 -213 -260 -119
Net Cash From Investing Activities		 -17 -17 -432 115 -27 -63 -320 -1,644 -188 -150 -193
Net Cash From Continuing Investing Activities		 -17 -17 -432 115 -27 -63 -320 -1,644 -188 -150 -193
Purchase of Property, Plant & Equipment		 -17 -12 -417 -32 -27 -65 -293 -141 -209 -195 -188
Purchase of Investments		 - - - - 0.00 0.00 -67 -64 -60 -7.20 0.00
Sale of Property, Plant & Equipment		 - 0.00 - 147 - - - 0.00 0.00 9.30 0.00
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 3.80 53 78 63 0.00
Other Investing Activities, net		 - - - 0.00 0.00 1.61 37 18 3.50 -20 -4.50
Net Cash From Financing Activities		 -29 -17 271 -244 -98 -130 -173 252 -266 49 156
Net Cash From Continuing Financing Activities		 -29 -17 271 -244 -98 -130 -173 252 -266 49 156
Repayment of Debt		 -0.59 -4.46 -8.68 -204 -54 0.00 -0.30 -2,388 -226 53 -2,404
Repurchase of Common Equity		 -31 -20 -0.54 -4.34 0.00 -44 -104 -74 -7.20 0.00 0.00
Issuance of Debt		 0.00 0.00 255 - - - 0.00 2,735 0.00 0.00 2,559
Issuance of Common Equity		 2.91 8.58 25 17 15 9.61 7.60 26 12 5.00 6.10
Other Financing Activities, net		 -0.64 -0.75 -0.60 -52 -59 -96 -77 -46 -44 -9.60 -5.40
Effect of Exchange Rate Changes		 -0.02 -0.01 0.02 0.37 0.11 1.00 -0.40 -2.00 -1.20 -2.90 3.00
Cash Interest Paid		 7.00 6.49 9.14 7.93 2.30 0.48 0.00 95 150 178 172
Cash Income Taxes Paid		 1.92 0.49 1.27 6.92 2.19 110 236 265 87 42 0.00

Quarterly Cash Flow Statements for QuidelOrtho

This table details how cash moves in and out of QuidelOrtho's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
Net Change in Cash & Equivalents		 -30 -41 29 37 -46 29 25 -54 72 -29 -17
Net Cash From Operating Activities		 80 -0.70 -98 118 64 66 -47 -46 132 -33 -111
Net Cash From Continuing Operating Activities		 80 -0.70 -98 118 64 66 -47 -46 132 -33 -111
Net Income / (Loss) Continuing Operations		 7.00 -1,706 -148 -20 -178 -13 -255 -733 -131 -92 -93
Consolidated Net Income / (Loss)		 7.00 -1,706 -148 -20 -178 -13 -255 -733 -131 -92 -93
Depreciation Expense		 115 115 116 113 109 107 110 112 113 113 117
Non-Cash Adjustments To Reconcile Net Income		 14 1,753 68 12 108 12 164 727 11 11 -13
Changes in Operating Assets and Liabilities, net		 -56 -163 -134 12 25 -40 -77 -141 139 -65 -139
Net Cash From Investing Activities		 -55 -20 -35 -57 -38 -56 -33 -54 -50 -34 -107
Net Cash From Continuing Investing Activities		 -55 -20 -35 -57 -38 -56 -33 -54 -50 -34 -107
Purchase of Property, Plant & Equipment		 -49 -66 -35 -47 -47 -56 -38 -49 -45 -34 -26
Net Cash From Financing Activities		 -58 -19 163 -26 -69 18 103 46 -11 38 201
Net Cash From Continuing Financing Activities		 -58 -19 163 -26 -69 18 103 46 -11 38 201
Repayment of Debt		 -51 -12 161 -28 -68 16 104 -2,506 -19 28 100
Issuance of Debt		 -2.90 -1.30 -0.30 1.60 - 0.00 1.90 2,550 7.80 11 101
Issuance of Common Equity		 3.50 0.50 4.10 0.40 - 3.00 0.10 2.90 0.10 1.80 0.40
Other Financing Activities, net		 -0.50 -5.80 -2.50 -0.40 -0.90 -1.40 -2.70 -0.90 -0.40 -2.70 -0.90
Effect of Exchange Rate Changes		 2.10 -1.10 -0.80 1.40 -2.40 1.70 1.00 -0.20 0.50 0.00 0.30

Annual Balance Sheets for QuidelOrtho

This table presents QuidelOrtho's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Total Assets		 407 388 935 806 911 1,871 2,430 8,856 8,563 6,424 5,769
Total Current Assets		 241 225 331 193 222 1,142 1,440 1,575 1,311 1,219 1,447
Cash & Equivalents		 191 170 36 44 53 490 803 293 119 98 170
Accounts Receivable		 18 25 67 59 94 498 378 454 303 282 417
Inventories, net		 26 26 67 67 58 114 199 524 578 534 578
Prepaid Expenses		 4.34 4.85 14 24 17 41 35 252 262 262 251
Other Current Assets		 - 0.00 147 - - - - - 0.00 42 32
Plant, Property, & Equipment, net		 53 51 62 74 80 110 349 1,339 1,444 1,380 1,358
Total Noncurrent Assets		 113 112 542 539 609 618 641 5,942 5,809 3,825 2,964
Intangible Assets		 32 28 204 175 148 122 99 3,124 2,934 2,736 2,564
Other Noncurrent Operating Assets		 0.73 0.53 1.58 4.83 99 114 147 304 349 439 400
Total Liabilities & Shareholders' Equity		 407 388 935 806 911 1,871 2,430 8,856 8,563 6,424 5,769
Total Liabilities		 188 188 708 381 351 538 501 3,921 3,557 3,439 3,849
Total Current Liabilities		 31 34 128 160 126 337 324 1,007 834 999 966
Short-Term Debt		 1.29 2.83 26 58 19 5.99 5.99 208 140 342 178
Accounts Payable		 8.68 16 27 25 27 86 101 283 295 246 279
Current Deferred & Payable Income Tax Liabilities		 - - - - 0.00 128 67 52 11 5.40 12
Current Employee Benefit Liabilities		 9.63 9.64 16 19 17 35 40 139 85 117 120
Other Current Liabilities		 7.58 5.10 13 13 21 40 67 325 303 289 377
Total Noncurrent Liabilities		 157 154 580 221 225 202 177 2,914 2,723 2,440 2,883
Long-Term Debt		 143 144 377 53 - - - 2,431 2,275 2,141 2,472
Noncurrent Deferred & Payable Income Tax Liabilities		 1.97 0.06 0.43 - - - - 213 192 77 90
Other Noncurrent Operating Liabilities		 4.49 9.61 202 168 225 202 177 270 256 223 321
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 219 201 227 426 560 1,333 1,929 4,935 5,006 2,985 1,921
Total Preferred & Common Equity		 219 201 227 426 560 1,333 1,929 4,935 5,006 2,985 1,921
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 219 201 227 426 560 1,333 1,929 4,935 5,006 2,985 1,921
Common Stock		 209 205 240 364 426 388 280 2,804 2,848 2,885 2,932
Retained Earnings		 9.55 -4.26 -12 62 135 945 1,649 2,198 2,188 136 -996
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.05 0.00 -0.14 -0.46 -0.43 0.36 -68 -30 -36 -15

Quarterly Balance Sheets for QuidelOrtho

This table presents QuidelOrtho's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2024 9/29/2024 3/30/2025 6/29/2025 9/28/2025 3/29/2026 6/28/2026
Total Assets		 6,689 6,801 6,462 6,379 5,675 5,629 5,715
Total Current Assets		 1,341 1,413 1,258 1,282 1,367 1,377 1,377
Cash & Equivalents		 107 144 127 152 98 140 123
Accounts Receivable		 270 295 286 275 387 360 352
Inventories, net		 602 577 563 579 614 612 619
Prepaid Expenses		 310 344 240 234 236 233 250
Other Current Assets		 53 53 42 42 32 32 32
Plant, Property, & Equipment, net		 1,327 1,364 1,399 1,315 1,323 1,339 1,339
Total Noncurrent Assets		 4,021 4,025 3,804 3,783 2,985 2,912 3,000
Intangible Assets		 2,836 2,796 2,698 2,661 2,608 2,520 2,678
Other Noncurrent Operating Assets		 428 432 435 411 377 392 322
Total Liabilities & Shareholders' Equity		 6,689 6,801 6,462 6,379 5,675 5,629 5,715
Total Liabilities		 3,516 3,614 3,464 3,586 3,639 3,777 3,940
Total Current Liabilities		 932 1,027 1,047 1,142 768 962 993
Short-Term Debt		 356 374 394 534 163 228 356
Accounts Payable		 237 247 231 219 214 244 237
Current Deferred & Payable Income Tax Liabilities		 3.50 1.90 5.80 26 0.90 13 14
Current Employee Benefit Liabilities		 86 113 135 85 104 135 77
Other Current Liabilities		 249 291 281 278 287 343 310
Total Noncurrent Liabilities		 2,583 2,587 2,417 2,444 2,871 2,815 2,947
Long-Term Debt		 2,207 2,177 2,106 2,072 2,497 2,460 2,535
Noncurrent Deferred & Payable Income Tax Liabilities		 128 117 78 83 80 87 122
Other Noncurrent Operating Liabilities		 248 293 233 289 294 268 290
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,174 3,187 2,997 2,793 2,036 1,851 1,775
Total Preferred & Common Equity		 3,174 3,187 2,997 2,793 2,036 1,851 1,775
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,174 3,187 2,997 2,793 2,036 1,851 1,775
Common Stock		 2,864 2,876 2,898 2,909 2,921 2,943 2,955
Retained Earnings		 334 314 123 -132 -865 -1,088 -1,181
Accumulated Other Comprehensive Income / (Loss)		 -25 -3.50 -24 16 -20 -4.10 0.80

Annual Metrics And Ratios for QuidelOrtho

This table displays calculated financial ratios and metrics derived from QuidelOrtho's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
DEI Shares Outstanding		 33,254,841.00 32,643,557.00 33,996,891.00 39,337,111.00 41,652,138.00 42,067,646.00 0.00 0.00 0.00 67,256,717.00 67,931,540.00
DEI Adjusted Shares Outstanding		 33,254,841.00 32,643,557.00 33,996,891.00 39,337,111.00 41,652,138.00 42,067,646.00 0.00 0.00 0.00 67,256,717.00 67,931,540.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.18 -0.42 -0.24 1.89 1.75 19.26 0.00 0.00 0.00 -30.51 -16.66
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 6.50% -2.31% 44.96% 88.05% 2.41% 210.66% 0.00% 92.28% -8.21% -7.17% -1.89%
EBITDA Growth		 60.66% -23.72% 136.25% 161.49% -5.12% 681.13% 0.00% 16.73% -48.56% -363.09% 68.11%
EBIT Growth		 129.74% -262.13% 315.18% 904.28% -3.35% 1,043.63% 0.00% -7.78% -85.82% -1,760.76% 53.00%
NOPAT Growth		 129.74% -262.13% 315.18% 1,579.12% -21.97% 842.75% 0.00% -11.23% -84.52% -1,509.71% 53.12%
Net Income Growth		 14.07% -127.14% 40.87% 1,008.55% -1.70% 1,011.18% 0.00% -22.08% -101.84% -20,216.83% 44.84%
EPS Growth		 14.29% -133.33% 42.86% 875.00% -6.99% 975.14% 0.00% -41.81% -101.57% -20,260.00% 45.35%
Operating Cash Flow Growth		 3.35% -67.96% 134.52% 392.06% -1.36% 368.28% 0.00% 9.85% -68.35% -70.38% 26.75%
Free Cash Flow Firm Growth		 -65.49% -153.92% -7,167.84% 81.27% 550.33% 45.43% 0.00% 0.00% 100.89% 761.76% -35.51%
Invested Capital Growth		 -4.63% 1.44% 233.59% 31.79% -32.93% 61.46% 0.00% 0.00% 0.54% -25.90% -18.04%
Revenue Q/Q Growth		 -5.94% -31.73% 120.07% 3.51% 3.80% 65.40% 0.00% 0.00% 0.00% 0.00% 0.58%
EBITDA Q/Q Growth		 -25.96% 170.23% 8.44% 7.46% 4.63% 110.72% 0.00% 0.00% 0.00% 0.00% 8.02%
EBIT Q/Q Growth		 -78.92% 77.99% -60.30% 32.72% 8.83% 121.68% 0.00% 0.00% 0.00% 0.00% 4.04%
NOPAT Q/Q Growth		 -67.32% 77.99% -19.44% 49.75% -7.30% 112.97% 0.00% 0.00% 0.00% 0.00% 3.58%
Net Income Q/Q Growth		 -530.83% 41.30% -230.45% 102.60% -2.48% 118.53% 0.00% 0.00% 0.00% 0.00% 4.04%
EPS Q/Q Growth		 -700.00% 41.67% -220.00% 106.67% -4.95% 118.05% 0.00% 0.00% 0.00% 0.00% 3.41%
Operating Cash Flow Q/Q Growth		 -4.11% -0.06% -16.30% 30.66% 3.47% 164.21% 0.00% 0.00% 0.00% -16.75% 184.32%
Free Cash Flow Firm Q/Q Growth		 105.40% 75.54% -10,949.68% 63.98% 546.84% 271.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -3.23% -6.44% 193.61% 59.74% -1.14% 8.23% 0.00% 0.00% 0.00% 0.00% -4.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.22% 58.31% 56.22% 60.45% 59.98% 81.17% 75.26% 59.28% 49.94% 46.23% 46.67%
EBITDA Margin		 16.21% 12.66% 20.63% 28.68% 26.57% 66.81% 56.45% 34.27% 19.20% -54.43% -17.69%
Operating Margin		 1.40% -2.32% 3.44% 18.37% 17.33% 63.81% 53.34% 25.83% 4.64% -70.46% -33.67%
EBIT Margin		 1.40% -2.32% 3.44% 18.37% 17.33% 63.81% 53.34% 25.58% 3.95% -70.72% -33.88%
Profit (Net Income) Margin		 -3.10% -7.21% -2.94% 14.20% 13.63% 48.76% 41.46% 16.80% -0.34% -73.74% -41.45%
Tax Burden Percent		 65.39% 85.24% 101.61% 117.04% 94.48% 77.89% 78.22% 74.56% 34.71% 96.27% 102.18%
Interest Burden Percent		 -339.55% 364.92% -84.13% 66.07% 83.24% 98.11% 99.36% 88.07% -24.56% 108.31% 119.75%
Effective Tax Rate		 0.00% 0.00% 0.00% -17.04% 5.52% 22.11% 21.78% 25.44% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 1.06% -1.76% 1.73% 16.29% 13.38% 120.18% 0.00% 17.46% 1.35% -21.76% -13.17%
ROIC Less NNEP Spread (ROIC-NNEP)		 16.50% 31.04% -6.87% 9.67% 9.46% 126.19% 0.00% 10.38% -3.42% -51.14% -33.25%
Return on Net Nonoperating Assets (RNNOA)		 -3.69% -4.83% -5.55% 49.04% 12.67% -34.55% 0.00% 4.78% -1.55% -29.60% -32.98%
Return on Equity (ROE)		 -2.62% -6.59% -3.82% 65.33% 26.05% 85.63% 0.00% 22.24% -0.20% -51.36% -46.15%
Cash Return on Invested Capital (CROIC)		 5.81% -3.19% -106.02% -11.14% 52.80% 73.16% 0.00% -182.54% 0.81% 7.99% 6.65%
Operating Return on Assets (OROA)		 0.64% -1.12% 1.44% 11.02% 10.80% 76.23% 0.00% 9.44% 1.36% -26.26% -15.17%
Return on Assets (ROA)		 -1.42% -3.47% -1.23% 8.52% 8.49% 58.25% 0.00% 6.20% -0.12% -27.38% -18.56%
Return on Common Equity (ROCE)		 -2.62% -6.59% -3.82% 65.33% 26.05% 85.63% 0.00% 22.24% -0.20% -51.36% -46.15%
Return on Equity Simple (ROE_SIMPLE)		 -2.78% -6.88% -3.60% 0.00% 13.03% 60.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 1.92 -3.11 6.69 112 88 826 709 629 97 -1,373 -643
NOPAT Margin		 0.98% -1.62% 2.41% 21.50% 16.38% 49.70% 41.72% 19.26% 3.25% -49.32% -23.57%
Net Nonoperating Expense Percent (NNEP)		 -15.43% -32.79% 8.60% 6.62% 3.92% -6.02% 0.00% 7.07% 4.76% 29.38% 20.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 8.31% 1.31% -25.10% -14.08%
Cost of Revenue to Revenue		 39.78% 41.69% 43.78% 39.55% 40.02% 18.83% 24.74% 40.72% 50.06% 53.77% 53.33%
SG&A Expenses to Revenue		 13.80% 13.75% 10.51% 8.61% 9.86% 4.01% 14.11% 19.39% 26.36% 29.42% 30.91%
R&D to Revenue		 18.11% 20.18% 12.11% 9.89% 9.83% 5.07% 5.63% 5.75% 8.17% 7.86% 6.82%
Operating Expenses to Revenue		 58.82% 60.63% 52.78% 42.08% 42.64% 17.36% 21.92% 33.45% 45.30% 116.69% 80.34%
Earnings before Interest and Taxes (EBIT)		 2.74 -4.44 9.55 96 93 1,060 906 836 119 -1,968 -925
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 32 24 57 150 142 1,110 959 1,119 576 -1,515 -483
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.22 3.49 6.49 0.00 5.58 5.67 0.00 1.00 0.98 1.00 1.03
Price to Tangible Book Value (P/TBV)		 6.64 7.84 0.00 0.00 41.84 8.65 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.59 3.65 5.31 3.68 5.84 4.55 3.41 1.51 1.64 1.07 0.73
Price to Earnings (P/E)		 0.00 0.00 0.00 25.89 42.86 9.33 8.22 8.96 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 3.86% 2.33% 10.72% 12.16% 11.16% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.77 3.80 3.10 2.45 5.88 8.33 0.00 1.00 0.99 1.00 1.02
Enterprise Value to Revenue (EV/Rev)		 3.38 3.53 6.63 3.68 5.78 4.26 0.00 2.20 2.39 1.93 1.64
Enterprise Value to EBITDA (EV/EBITDA)		 20.83 27.92 32.14 12.82 21.75 6.37 0.00 6.42 12.44 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 241.81 0.00 192.78 20.02 33.34 6.67 0.00 8.60 60.45 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 345.45 0.00 275.40 17.11 35.28 8.56 0.00 11.43 73.57 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.95 57.29 66.46 14.09 22.98 11.23 0.00 8.12 25.56 64.56 42.46
Enterprise Value to Free Cash Flow (EV/FCFF)		 63.32 0.00 0.00 0.00 8.94 14.07 0.00 0.00 122.51 10.63 13.75
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.68 0.73 1.78 0.00 0.03 0.00 0.00 0.53 0.48 0.83 1.38
Long-Term Debt to Equity		 0.67 0.72 1.66 0.00 0.00 0.00 0.00 0.49 0.45 0.72 1.29
Financial Leverage		 -0.22 -0.16 0.81 5.07 1.34 -0.27 0.00 0.46 0.45 0.58 0.99
Leverage Ratio		 1.84 1.90 3.09 7.67 3.07 1.47 0.00 1.79 1.75 1.88 2.49
Compound Leverage Factor		 -6.25 6.92 -2.60 5.07 2.55 1.44 0.00 1.58 -0.43 2.03 2.98
Debt to Total Capital		 40.46% 42.31% 64.00% 0.00% 3.22% 0.45% 0.00% 34.84% 32.54% 45.41% 57.98%
Short-Term Debt to Total Capital		 0.35% 0.81% 4.20% 0.00% 3.22% 0.45% 0.00% 2.74% 1.88% 6.25% 3.90%
Long-Term Debt to Total Capital		 40.11% 41.50% 59.80% 0.00% 0.00% 0.00% 0.00% 32.10% 30.66% 39.16% 54.08%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 59.54% 57.69% 36.00% 0.00% 96.78% 99.55% 0.00% 65.16% 67.46% 54.59% 42.02%
Debt to EBITDA		 4.68 6.07 7.05 0.00 0.13 0.01 0.00 2.36 4.19 -1.64 -5.49
Net Debt to EBITDA		 -1.35 -0.92 6.42 0.00 -0.24 -0.44 0.00 2.03 3.89 -1.57 -5.14
Long-Term Debt to EBITDA		 4.63 5.95 6.59 0.00 0.00 0.00 0.00 2.17 3.95 -1.41 -5.12
Debt to NOPAT		 77.54 -47.36 60.38 0.00 0.21 0.01 0.00 4.19 24.80 -1.81 -4.12
Net Debt to NOPAT		 -22.39 7.19 54.99 0.00 -0.39 -0.59 0.00 3.61 23.00 -1.74 -3.85
Long-Term Debt to NOPAT		 76.87 -46.45 56.42 0.00 0.00 0.00 0.00 3.86 23.36 -1.56 -3.84
Altman Z-Score		 3.41 3.27 1.82 51.86 6.60 12.40 0.00 1.86 1.65 0.01 0.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.81 6.71 2.58 0.00 1.77 3.39 0.00 1.56 1.57 1.22 1.50
Quick Ratio		 6.81 5.79 0.80 0.00 1.17 2.93 0.00 0.79 0.56 0.38 0.61
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 10 -5.64 -410 -77 346 503 0.00 -6,578 58 504 325
Operating Cash Flow to CapEx		 216.53% 99.21% 6.64% 0.00% 493.90% 969.96% 275.24% 628.32% 133.87% 44.67% 55.90%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -9.29 462.20 48.42 0.00 -65.98 0.40 3.08 1.78
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 16.50 179.79 60.65 138.95 8.88 1.90 0.51 0.58
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 30.42 143.39 54.39 88.47 7.47 0.48 -0.63 -0.45
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.46 0.48 0.42 0.60 0.62 1.19 0.00 0.37 0.34 0.37 0.45
Accounts Receivable Turnover		 7.42 8.83 6.04 0.00 0.00 5.61 0.00 7.20 7.92 9.50 7.81
Inventory Turnover		 3.05 3.05 2.61 0.00 0.00 3.64 0.00 2.54 2.72 2.69 2.62
Fixed Asset Turnover		 3.85 3.71 4.94 0.00 0.00 17.47 0.00 2.44 2.15 1.97 1.99
Accounts Payable Turnover		 7.40 6.46 5.61 0.00 0.00 5.54 0.00 4.69 5.19 5.53 5.54
Days Sales Outstanding (DSO)		 49.19 41.33 60.48 0.00 0.00 65.04 0.00 50.73 46.10 38.41 46.75
Days Inventory Outstanding (DIO)		 119.64 119.80 139.76 0.00 0.00 100.28 0.00 143.85 134.00 135.56 139.29
Days Payable Outstanding (DPO)		 49.34 56.49 65.02 0.00 0.00 65.94 0.00 77.76 70.30 65.96 65.86
Cash Conversion Cycle (CCC)		 119.49 104.64 135.21 0.00 0.00 99.38 0.00 116.82 109.80 108.01 120.19
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 176 178 595 784 526 849 0.00 7,207 7,246 5,369 4,401
Invested Capital Turnover		 1.09 1.08 0.72 0.76 0.82 2.42 0.00 0.91 0.41 0.44 0.56
Increase / (Decrease) in Invested Capital		 -8.54 2.53 416 189 -258 323 0.00 7,207 39 -1,877 -968
Enterprise Value (EV)		 662 677 1,841 1,920 3,091 7,073 0.00 7,190 7,163 5,358 4,467
Market Capitalization		 705 699 1,474 1,920 3,125 7,557 5,791 4,917 4,923 2,974 1,987
Book Value per Share		 $6.58 $6.15 $6.68 $0.00 $13.44 $31.68 $0.00 $86.88 $74.94 $44.37 $28.27
Tangible Book Value per Share		 $3.19 $2.73 ($9.23) $0.00 $1.79 $20.76 $0.00 ($11.73) ($6.29) ($5.96) ($9.47)
Total Capital		 367 348 631 0.00 578 1,339 0.00 7,573 7,421 5,468 4,571
Total Debt		 149 147 404 0.00 19 5.99 0.00 2,638 2,415 2,483 2,650
Total Long-Term Debt		 147 144 377 0.00 0.00 0.00 0.00 2,431 2,275 2,141 2,472
Net Debt		 -43 -22 368 0.00 -34 -484 0.00 2,272 2,240 2,385 2,480
Capital Expenditures (CapEx)		 17 12 417 -115 27 65 293 141 209 186 188
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 20 25 193 -160 62 321 0.00 431 449 464 490
Debt-free Net Working Capital (DFNWC)		 211 195 229 -160 115 811 0.00 776 617 562 660
Net Working Capital (NWC)		 210 192 203 -160 96 805 0.00 568 477 220 481
Net Nonoperating Expense (NNE)		 8.00 11 15 38 15 16 4.46 80 107 679 488
Net Nonoperating Obligations (NNO)		 -43 -22 368 784 -34 -484 0.00 2,272 2,240 2,385 2,480
Total Depreciation and Amortization (D&A)		 29 29 48 54 49 50 53 284 457 453 442
Debt-free, Cash-free Net Working Capital to Revenue		 9.99% 13.10% 69.59% -30.58% 11.63% 19.35% 0.00% 13.18% 14.98% 16.66% 17.94%
Debt-free Net Working Capital to Revenue		 107.64% 101.57% 82.58% -30.58% 21.49% 48.83% 0.00% 23.75% 20.57% 20.19% 24.16%
Net Working Capital to Revenue		 106.99% 100.09% 73.05% -30.58% 18.01% 48.47% 0.00% 17.39% 15.90% 7.91% 17.63%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.18) ($0.42) ($0.24) $1.95 $1.78 $19.24 $0.00 $0.00 ($0.15) ($30.54) ($16.69)
Adjusted Weighted Average Basic Shares Outstanding		 34.10M 32.95M 34.85M 38.00M 40.86M 42.12M 0.00 0.00 66.80M 67.20M 67.80M
Adjusted Diluted Earnings per Share		 ($0.18) ($0.42) ($0.24) $1.86 $1.73 $18.60 $0.00 $0.00 ($0.15) ($30.54) ($16.69)
Adjusted Weighted Average Diluted Shares Outstanding		 34.10M 32.95M 34.85M 42.55M 43.11M 43.59M 0.00 0.00 66.80M 67.20M 67.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.42) ($0.24) $1.95 $1.78 $19.24 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 32.27M 32.71M 33.73M 39.45M 41.88M 42.32M 0.00 0.00 66.85M 67.45M 68.08M
Normalized Net Operating Profit after Tax (NOPAT)		 3.59 -2.61 18 77 99 829 716 733 180 32 38
Normalized NOPAT Margin		 1.83% -1.36% 6.57% 14.76% 18.44% 49.87% 42.16% 22.43% 6.00% 1.15% 1.41%
Pre Tax Income Margin		 -4.74% -8.45% -2.89% 12.14% 14.43% 62.61% 53.00% 22.53% -0.97% -76.59% -40.57%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 11.61 123.95 102.11 156.22 8.38 0.80 -12.04 -5.06
NOPAT to Interest Expense		 0.00 0.00 0.00 13.59 117.11 79.53 122.18 6.31 0.66 -8.40 -3.52
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 25.52 87.55 95.86 105.74 6.97 -0.62 -13.17 -6.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 27.50 80.71 73.28 71.70 4.90 -0.76 -9.53 -4.55
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -508.87% -146.06% -6.63% 5.86% 0.00% 5.39% 14.70% 13.54% -71.29% 0.00% 0.00%

Quarterly Metrics And Ratios for QuidelOrtho

This table displays calculated financial ratios and metrics derived from QuidelOrtho's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
DEI Shares Outstanding		 66,849,490.00 66,849,490.00 67,235,394.00 67,256,717.00 67,446,544.00 67,625,872.00 67,900,466.00 67,931,540.00 68,081,767.00 68,190,989.00
DEI Adjusted Shares Outstanding		 66,849,490.00 66,849,490.00 67,235,394.00 67,256,717.00 67,446,544.00 67,625,872.00 67,900,466.00 67,931,540.00 68,081,767.00 68,190,989.00
DEI Earnings Per Adjusted Shares Outstanding		 -25.52 -2.21 -0.30 -2.65 -0.19 -3.78 -10.80 -1.92 -1.35 -1.36
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -4.22% -2.27% 0.00% -2.56% -3.63% -3.74% 2.23% -10.54% 2.77%
EBITDA Growth		 0.00% -124.68% -5.99% 0.00% 108.41% -1,258.62% -566.67% 467.78% -38.90% 214.47%
EBIT Growth		 0.00% -336.92% -36.49% 0.00% 101.77% -55.13% -5,104.96% 38.78% -191.03% 85.99%
NOPAT Growth		 0.00% -336.80% -42.97% 0.00% 101.85% -53.79% -4,798.67% 33.96% -197.55% 87.94%
Net Income Growth		 0.00% -177.63% -56.69% 0.00% 99.26% -72.92% -3,583.42% 26.74% -622.83% 63.63%
EPS Growth		 0.00% -175.00% -57.89% 0.00% 99.25% -71.36% -3,493.33% 23.23% -610.53% 63.93%
Operating Cash Flow Growth		 0.00% 0.00% 184.10% -20.77% 9,471.43% 52.20% -138.59% 107.06% -150.30% -136.32%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 104.49% 109.01% 0.00% 117.74% 168.99%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -6.80% -17.81% -18.04% -18.08% -13.43%
Revenue Q/Q Growth		 0.00% -10.41% 14.14% -2.65% -2.12% -11.39% 14.01% 3.39% -14.34% 1.79%
EBITDA Q/Q Growth		 0.00% 99.65% 2,293.10% -92.92% 1,436.67% -156.98% -653.30% 108.61% 65.36% 6.75%
EBIT Q/Q Growth		 0.00% 93.07% 111.57% -811.35% 131.11% -706.09% -273.19% 91.30% 53.75% 6.69%
NOPAT Q/Q Growth		 0.00% 93.32% 112.77% -769.33% 132.47% -654.29% -290.04% 90.59% 52.04% 31.45%
Net Income Q/Q Growth		 0.00% 91.34% 86.53% -796.48% 92.88% -1,911.02% -187.00% 82.17% 29.76% -1.20%
EPS Q/Q Growth		 0.00% 91.37% 86.36% -746.67% 92.52% -1,884.21% -185.94% 81.91% 30.77% -0.74%
Operating Cash Flow Q/Q Growth		 -100.87% -13,885.71% 220.43% -45.97% 2.98% -171.34% 2.78% 389.89% -125.02% -235.15%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 2.27% 100.00% 0.00% 104.79% 96.15% 83.39% 2.88% -27.32%
Invested Capital Q/Q Growth		 0.00% 0.00% -0.65% -4.01% 0.01% -2.28% -12.39% -4.27% -0.04% 3.26%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 46.71% 43.33% 48.45% 46.07% 49.55% 44.78% 47.95% 44.28% 42.56% 43.26%
EBITDA Margin		 -231.36% -0.91% 17.49% 1.27% 19.96% -12.84% -84.81% 7.06% 13.63% 14.30%
Operating Margin		 -247.26% -18.45% 2.06% -14.18% 4.71% -29.43% -100.70% -9.16% -5.13% -3.46%
EBIT Margin		 -247.52% -19.14% 1.94% -14.17% 4.50% -30.80% -100.83% -8.49% -4.58% -4.20%
Profit (Net Income) Margin		 -239.94% -23.19% -2.74% -25.20% -1.83% -41.60% -104.73% -18.06% -14.81% -14.73%
Tax Burden Percent		 94.84% 90.67% 69.10% 126.61% 144.32% 111.24% 96.84% 116.28% 115.47% 114.41%
Interest Burden Percent		 102.22% 133.63% -204.26% 140.48% -28.21% 121.42% 107.26% 183.06% 279.93% 306.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -5.15% 3.39% -10.39% -37.55% -3.58% -1.95% -1.32%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -9.68% 0.40% -15.64% -47.20% -7.05% -4.78% -4.29%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% -7.74% 0.31% -12.87% -44.89% -6.99% -4.85% -4.91%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -12.88% 3.71% -23.26% -82.44% -10.58% -6.81% -6.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 9.38% 0.00% 0.00% 0.00% 6.65% 5.78% 2.60%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -5.26% 1.93% -12.92% -43.87% -3.80% -2.01% -1.86%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -9.36% -0.78% -17.46% -45.57% -8.09% -6.51% -6.51%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -12.88% 3.71% -23.26% -82.44% -10.58% -6.81% -6.23%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1,231 -82 11 -70 23 -126 -493 -46 -22 -15
NOPAT Margin		 -173.08% -12.91% 1.44% -9.93% 3.29% -20.60% -70.49% -6.41% -3.59% -2.42%
Net Nonoperating Expense Percent (NNEP)		 0.00% 5.33% 2.53% 4.53% 2.99% 5.25% 9.65% 3.47% 2.83% 2.97%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.43% 0.18% -1.29% 0.42% -2.34% -10.51% -1.02% -0.49% -0.33%
Cost of Revenue to Revenue		 53.29% 56.67% 51.55% 53.93% 50.45% 55.22% 52.05% 55.72% 57.44% 56.74%
SG&A Expenses to Revenue		 29.92% 31.00% 26.50% 30.47% 27.92% 29.83% 28.75% 36.80% 32.19% 30.20%
R&D to Revenue		 8.33% 8.84% 7.69% 6.68% 7.68% 7.44% 5.93% 6.33% 7.24% 7.72%
Operating Expenses to Revenue		 293.97% 61.77% 46.39% 60.26% 44.85% 74.21% 148.65% 53.44% 47.69% 46.71%
Earnings before Interest and Taxes (EBIT)		 -1,760 -122 14 -100 31 -189 -706 -61 -28 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1,645 -5.80 127 9.00 138 -79 -594 51 85 90
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.70 0.96 1.00 0.79 0.70 0.95 1.03 0.54 0.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 1.07 0.85 0.71 0.71 0.73 0.38 0.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.83 0.98 1.00 0.88 0.84 0.98 1.02 0.81 0.82
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 1.93 1.71 1.61 1.65 1.64 1.34 1.39
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 17.59 22.53 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 201.10 54.89 64.56 31.67 22.00 121.28 42.46 538.73 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.75 12.60 29.12
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.81 0.80 0.83 0.83 0.93 1.31 1.38 1.45 1.63
Long-Term Debt to Equity		 0.00 0.70 0.68 0.72 0.70 0.74 1.23 1.29 1.33 1.43
Financial Leverage		 0.00 0.77 0.76 0.80 0.79 0.82 0.95 0.99 1.01 1.14
Leverage Ratio		 0.00 2.11 2.13 1.88 2.16 2.19 2.39 2.49 2.49 2.65
Compound Leverage Factor		 0.00 2.82 -4.36 2.63 -0.61 2.66 2.56 4.55 6.98 8.11
Debt to Total Capital		 0.00% 44.68% 44.45% 45.41% 45.47% 48.27% 56.63% 57.98% 59.21% 61.96%
Short-Term Debt to Total Capital		 0.00% 6.21% 6.52% 6.25% 7.16% 9.89% 3.46% 3.90% 5.03% 7.62%
Long-Term Debt to Total Capital		 0.00% 38.47% 37.94% 39.16% 38.31% 38.38% 53.17% 54.08% 54.19% 54.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 55.32% 55.55% 54.59% 54.53% 51.73% 43.37% 42.02% 40.79% 38.04%
Debt to EBITDA		 0.00 0.00 0.00 -1.64 9.30 13.32 -5.06 -5.49 -5.01 -7.86
Net Debt to EBITDA		 0.00 0.00 0.00 -1.57 8.83 12.54 -4.88 -5.14 -4.75 -7.53
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -1.41 7.84 10.59 -4.75 -5.12 -4.58 -6.89
Debt to NOPAT		 0.00 0.00 0.00 -1.81 -20.97 -15.95 -3.98 -4.12 -3.90 -5.01
Net Debt to NOPAT		 0.00 0.00 0.00 -1.74 -19.90 -15.02 -3.84 -3.85 -3.70 -4.79
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -1.56 -17.67 -12.68 -3.74 -3.84 -3.57 -4.39
Altman Z-Score		 0.00 0.00 0.00 0.97 0.92 0.66 0.30 0.61 0.43 0.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 1.44 1.38 1.22 1.20 1.12 1.78 1.50 1.43 1.39
Quick Ratio		 0.00 0.40 0.43 0.38 0.39 0.37 0.63 0.61 0.52 0.48
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5,712 -5,583 0.00 -5,347 256 503 922 949 689
Operating Cash Flow to CapEx		 -1.06% -277.34% 253.55% 134.96% 116.73% -124.80% -92.48% 291.17% -97.06% -433.73%
Free Cash Flow to Firm to Interest Expense		 0.00 -139.33 -130.14 0.00 -133.67 6.33 9.82 18.08 18.56 12.60
Operating Cash Flow to Interest Expense		 -0.02 -2.39 2.75 1.57 1.64 -1.16 -0.89 2.59 -0.65 -2.02
Operating Cash Flow Less CapEx to Interest Expense		 -1.71 -3.25 1.66 0.41 0.24 -2.08 -1.85 1.70 -1.31 -2.49
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.37 0.43 0.42 0.44 0.45 0.44 0.44
Accounts Receivable Turnover		 0.00 0.00 0.00 9.50 9.67 10.07 7.97 7.81 8.23 8.53
Inventory Turnover		 0.00 0.00 0.00 2.69 2.60 2.45 2.41 2.62 2.49 2.47
Fixed Asset Turnover		 0.00 0.00 0.00 1.97 1.98 2.08 2.02 1.99 1.94 2.02
Accounts Payable Turnover		 0.00 0.00 0.00 5.53 6.35 6.33 6.22 5.54 6.17 6.51
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 38.41 37.76 36.25 45.81 46.75 44.36 42.79
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 135.56 140.13 149.12 151.50 139.29 146.59 147.53
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 65.96 57.45 57.62 58.64 65.86 59.20 56.09
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 108.01 120.44 127.75 138.67 120.19 131.75 134.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 5,630 5,593 5,369 5,370 5,247 4,597 4,401 4,399 4,543
Invested Capital Turnover		 0.00 0.00 0.00 0.52 1.03 0.50 0.53 0.56 0.54 0.55
Increase / (Decrease) in Invested Capital		 0.00 5,630 5,593 0.00 5,370 -383 -996 -968 -971 -705
Enterprise Value (EV)		 0.00 4,686 5,472 5,358 4,728 4,409 4,487 4,467 3,556 3,710
Market Capitalization		 3,207 2,229 3,066 2,974 2,355 1,954 1,926 1,987 1,008 942
Book Value per Share		 $0.00 $47.30 $47.40 $44.37 $44.44 $41.30 $29.99 $28.27 $27.19 $26.03
Tangible Book Value per Share		 $0.00 ($5.89) ($5.65) ($5.96) ($5.51) ($8.56) ($8.42) ($9.47) ($9.82) ($13.25)
Total Capital		 0.00 5,737 5,737 5,468 5,497 5,399 4,695 4,571 4,539 4,666
Total Debt		 0.00 2,564 2,550 2,483 2,500 2,606 2,659 2,650 2,688 2,891
Total Long-Term Debt		 0.00 2,207 2,177 2,141 2,106 2,072 2,497 2,472 2,460 2,535
Net Debt		 0.00 2,457 2,407 2,385 2,373 2,455 2,561 2,480 2,548 2,768
Capital Expenditures (CapEx)		 66 35 47 47 56 38 49 45 34 26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 658 615 464 478 522 663 490 502 616
Debt-free Net Working Capital (DFNWC)		 0.00 765 759 562 605 674 761 660 643 739
Net Working Capital (NWC)		 0.00 409 385 220 211 139 599 481 415 383
Net Nonoperating Expense (NNE)		 475 65 30 108 36 129 240 84 70 78
Net Nonoperating Obligations (NNO)		 0.00 2,457 2,407 2,385 2,373 2,455 2,561 2,480 2,548 2,768
Total Depreciation and Amortization (D&A)		 115 116 113 109 107 110 112 113 113 117
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 16.66% 17.28% 19.04% 24.43% 17.94% 18.91% 23.02%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 20.19% 21.88% 24.57% 28.05% 24.16% 24.19% 27.63%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 7.91% 7.63% 5.08% 22.06% 17.63% 15.60% 14.33%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.20) ($0.30) ($2.54) ($0.19) ($3.77) ($10.78) ($1.95) ($1.35) ($1.36)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 67.10M 67.30M 67.20M 67.50M 67.70M 68M 67.80M 68.20M 68.30M
Adjusted Diluted Earnings per Share		 $0.00 ($2.20) ($0.30) ($2.54) ($0.19) ($3.77) ($10.78) ($1.95) ($1.35) ($1.36)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 67.10M 67.30M 67.20M 67.50M 67.70M 68M 67.80M 68.20M 68.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 67.24M 67.26M 67.45M 67.63M 67.90M 67.93M 68.08M 68.19M 68.58M
Normalized Net Operating Profit after Tax (NOPAT)		 5.95 -21 36 11 34 -1.26 32 -26 -19 -11
Normalized NOPAT Margin		 0.84% -3.26% 4.99% 1.50% 4.92% -0.21% 4.52% -3.61% -3.09% -1.70%
Pre Tax Income Margin		 -253.01% -25.57% -3.96% -19.91% -1.27% -37.40% -108.14% -15.53% -12.83% -12.87%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -45.13 -2.97 0.33 -2.47 0.78 -4.67 -13.78 -1.20 -0.56 -0.48
NOPAT to Interest Expense		 -31.55 -2.01 0.24 -1.73 0.57 -3.12 -9.64 -0.91 -0.44 -0.28
EBIT Less CapEx to Interest Expense		 -46.82 -3.83 -0.76 -3.63 -0.63 -5.60 -14.74 -2.09 -1.22 -0.95
NOPAT Less CapEx to Interest Expense		 -33.25 -2.87 -0.84 -2.89 -0.83 -4.05 -10.60 -1.80 -1.10 -0.75
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

QuidelOrtho’s recent financial statements show a business recovering from large impairment and restructuring charges, but profitability and cash generation remain under pressure. The company’s latest quarter, Q2 2026, produced revenue of $630.9 million, up from $619.8 million in Q1 2026 and $613.9 million in Q2 2025. However, revenue remains below the $637.0 million reported in Q2 2024 and well below the $699.9 million recorded in Q3 2025.

Gross profit increased to $272.9 million in Q2 2026 from $263.8 million in Q1 2026, although the gross margin was approximately 43.3%, largely unchanged from Q2 2024 and slightly below the 44.8% margin in Q2 2025. Operating expenses declined modestly year over year, helped by lower selling, general and administrative costs and a smaller restructuring charge. As a result, the operating loss improved to $21.8 million, compared with losses of $31.8 million in Q1 2026 and $180.7 million in Q2 2025.

Despite the improvement in operating results, QuidelOrtho remained deeply unprofitable. Interest expense rose to $54.7 million in Q2 2026, contributing to a pretax loss of $81.2 million and a net loss of $92.9 million, or $1.36 per share. The latest loss was substantially better than the $255.4 million loss reported in Q2 2025, but the company has continued to report quarterly net losses since Q3 2023, excluding the benefit of substantial noncash adjustments.

Cash flow deteriorated in the latest quarter. Operating activities used $110.6 million in Q2 2026, compared with an outflow of $33.0 million in Q1 and $46.8 million in Q2 2025. The primary pressure came from a $138.6 million use of operating working capital. Capital expenditures declined to $25.5 million from $34.0 million in Q1, but investing activities still consumed $107.3 million. Financing activities provided $200.6 million, primarily reflecting debt issuance, which helped offset operating and investing cash outflows.

The balance sheet remains a significant consideration for investors. Cash and equivalents declined to $123.4 million from $140.4 million in Q1 2026 and $151.7 million a year earlier. Total debt increased to approximately $2.89 billion, while total shareholders’ equity fell to $1.77 billion from $2.79 billion in Q2 2025. Retained earnings were negative $1.18 billion, reflecting the company’s cumulative losses. QuidelOrtho also held $2.68 billion of intangible assets, making asset quality and future impairment risk important factors to monitor.

  • Revenue improved sequentially and year over year: Q2 2026 revenue rose approximately 1.8% from Q1 2026 and 2.8% from Q2 2025.
  • Operating losses narrowed materially: The Q2 2026 operating loss of $21.8 million was substantially better than the $180.7 million loss in Q2 2025, when restructuring and impairment-related costs were much higher.
  • Net losses improved: The quarterly net loss declined to $92.9 million from $255.4 million a year earlier and $130.7 million in Q4 2025.
  • Restructuring costs moderated: The restructuring charge fell to $6.5 million in Q2 2026 from $178.9 million in Q2 2025 and $29.0 million in Q4 2025, which could support future margin improvement if additional charges continue to decline.
  • Capital spending decreased: Purchases of property, plant and equipment fell to $25.5 million in Q2 2026 from $34.0 million in Q1 and $37.5 million in Q2 2025, reducing one source of cash use.
  • Liquidity is adequate but not abundant: Current assets of $1.38 billion exceeded current liabilities of $993.4 million, but cash represented only $123.4 million of current assets, with much of the remainder tied up in receivables, inventory and prepaid expenses.
  • Share count has been relatively stable: Weighted average diluted shares increased modestly to 68.3 million in Q2 2026 from 67.7 million in Q2 2025, limiting but not eliminating dilution concerns.
  • Operating cash flow turned sharply negative: QuidelOrtho used $110.6 million in operating cash during Q2 2026, indicating that reported improvements in accounting earnings have not yet translated into cash generation.
  • Debt and interest costs remain elevated: Total debt was approximately $2.89 billion and quarterly interest expense reached $54.7 million, creating a substantial burden while the company remains unprofitable.
  • Equity and cash balances are shrinking: Since Q2 2025, cash declined by roughly 19% and shareholders’ equity declined by approximately 36%, increasing the importance of a sustained return to positive earnings and free cash flow.
10/06/26 10:07 AM ETAI Generated. May Contain Errors.

QuidelOrtho Financials - Frequently Asked Questions

According to the most recent income statement we have on file, QuidelOrtho's financial year ends in December. Their financial year 2025 ended on December 28, 2025.

QuidelOrtho's net income appears to be on a downward trend, with a most recent value of -$1.13 billion in 2025, falling from -$6.08 million in 2015. The previous period was -$2.05 billion in 2024. View QuidelOrtho's forecast to see where analysts expect QuidelOrtho to go next.

QuidelOrtho's total operating income in 2025 was -$919.20 million, based on the following breakdown:
  • Total Gross Profit: $1.27 billion
  • Total Operating Expenses: $2.19 billion

Over the last 10 years, QuidelOrtho's total revenue changed from $196.13 million in 2015 to $2.73 billion in 2025, a change of 1,292.0%.

In the past 8 quarters, QuidelOrtho's cash and equivalents has ranged from $98.10 million in Q3 2025 to $151.70 million in Q2 2025, and is currently $123.40 million as of their latest financial filing in Q2 2026.

QuidelOrtho had total debt of $2.65 billion at the end of 2025, a 6.7% increase from 2024, and a 1,683.3% increase since 2015.

Over the last 10 years, QuidelOrtho's book value per share changed from 6.58 in 2015 to 28.27 in 2025, a change of 329.9%.


Related Companies

Financial statements for NASDAQ:QDEL last updated on 10/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Stanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...
Brownstone Research | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Anthropic’s $40 million midterm move
Anthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...
The Oxford Club | Sponsoredtc pixel